Tempest Unveils 100% CR Rate in CAR-T Trials, New China Partnership
TPST sits 40% above its 52-week low of $0.84.
Summary
Tempest reported Q2 2026 results alongside a business update that includes several material developments. The company announced a strategic collaboration with Senlang Biotechnology to advance TPST-4003, its next-generation in vivo CAR-T candidate, with first patient dosing expected in Q4 2026. Interim data from partner Novatim's trials of TPST-2003 showed a 100% complete response rate in 15 CAR-T-naïve patients across two studies, with a favorable safety profile. The company also appointed two new board members and a Head of Business Development, and selected Cincinnati Children's AGCTC as its CDMO partner for TPST-2003. These updates follow a period of significant financial strain, including Nasdaq deficiency notices and a going concern warning, making the positive clinical data and new partnership particularly important for the company's outlook.
Updates
· SEC 8-K — Q2 net loss was $5.2 million, or $0.34 per share, with $0.8 million cash at June 30, 2026. The Senlang collaboration will begin with an investigator-initiated trial in China in about 10 patients with myasthenia gravis or multiple sclerosis.
At the time of this announcement, TPST was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.84 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.